BP
RETA

BBR Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

BBR Partners’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,666
Closed -$318K – 198
2022
Q3 		$318K Sell
12,666
-1,334
-10% -$37K 0.04% 133
2022
Q2 		$425K Hold
14,000
– – 0.05% 139
2022
Q1 		$459K Buy
+14,000
New +$415K 0.04% 140

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BBR Partners's RETA Position: Q4 2022 in Review

BBR Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 12,666 shares — an estimated $318K sold.

BBR Partners first reported a position in RETA in Q1 2022 and held it in 3 quarters. The position peaked at $459K in Q1 2022. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

  • BBR Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • BBR Partners sold 12,666 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $318K.
  • BBR Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 3 quarters.
  • BBR Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $459K in Q1 2022.
  • 168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on BBR Partners's 13F filing for Q4 2022, filed 13 Feb 2023.